Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
42.01 USD | +1.94% | +6.90% | +13.66% |
07/05 | Halozyme Therapeutics Q1 Non-GAAP Earnings, Revenue Rise; 2024 Guidance Reaffirmed | MT |
07/05 | Transcript : Halozyme Therapeutics, Inc., Q1 2024 Earnings Call, May 07, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+13.66% | 5.34B | |
+2.93% | 108B | |
+7.02% | 23.46B | |
-14.60% | 21.72B | |
-7.05% | 18.64B | |
-38.55% | 17.45B | |
-8.83% | 17.19B | |
+5.51% | 13.99B | |
+37.49% | 12.53B | |
+329.39% | 8.81B |
- Stock Market
- Equities
- HALO Stock
- News Halozyme Therapeutics, Inc.
- Halozyme Therapeutics Q4 Adjusted Earnings, Revenue Rise; Reiterates 2024 Guidance